Product
Supplier
Encyclopedia
Inquiry
Home > News > Market Flash > Glenmark's US Subsidiary Receives ANDA Approval for Two Drugs

Glenmark's US Subsidiary Receives ANDA Approval for Two Drugs

Chemical Weekly 2018-06-26

Glenmark Pharmaceuticals Inc., USA has been granted final approval by the US FDA for its Hailey 1.5/30 (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/30 mcg), the generic version of Loestrin 21 1.5/30 Tablets, of Allergan Pharmaceuticals International Ltd. and for Hailey Fe 1.5/30 (Nor ethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets, 1.5 mg/30 mcg), the generic version of Loestrin Fe 1.5/30, also of Allergan. According to IQVIA, sales data for the 12-month period ending April 2018, the Loestrin 21 1.5/30 tablets market achieved annual sales of approximately $24.2-mn and the Loestrin Fe 1.5/30 market achieved annual sales of approximately $41.3-mn.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.
Comment
Comment

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.